Literature DB >> 24500575

Rates of Inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference?

Andrea Messori1, Valeria Fadda1, Dario Maratea1, Sabrina Trippoli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24500575     DOI： 10.1055/s-0034-1367471

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN： 0094-6176            Impact factor:   4.180


× No keyword cloud information.
  2 in total

1.  Biological drugs for the treatment of moderate-to-severe psoriasis by subcutaneous route: determining statistical equivalence according to evidence-based methods.

Authors:  Andrea Messori; Valeria Fadda; Dario Maratea; Sabrina Trippoli; Roberta Gatto; Mauro De Rosa; Claudio Marinai
Journal:  Clin Drug Investig       Date:  2014-08       Impact factor: 2.859

2.  Testing the therapeutic equivalence of alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin as monotherapy or in combination with metformin in patients with type 2 diabetes.

Authors:  Andrea Messori; Valeria Fadda; Dario Maratea; Sabrina Trippoli; Claudio Marinai
Journal:  Diabetes Ther       Date:  2014-05-03       Impact factor: 2.945
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.